A key US Republican senator said he’s launched an investigation into the FDA’s recent denials of treatments for rare diseases https://t.co/0vqvGYOnwO ...

The FDA is already under fire from lawmakers for recent delays and rejections of new drugs for rare diseases. https://t.co/jk1gm7T6bc ...

Core Insights - Vanda Pharmaceuticals reported a 9% increase in total revenues for 2025, reaching $216.1 million, primarily driven by growth in Fanapt sales, despite a decline in Hetlioz revenue due to generic competition [2][4] Financial Performance - Full-year net product sales for Hetlioz decreased by 7% to $71.4 million, attributed to lower volume and pricing pressures from U.S. generic competition [1] - Fanapt net product sales increased by 24% to $117.3 million, supported by a 28% rise in total prescriptions and a 149% increase in new-to-brand prescriptions [3] - The company reported a full-year net loss of $220.5 million for 2025, significantly higher than the $18.9 million loss in 2024, largely due to a one-time, non-cash tax charge [5][7] Quarterly Performance - Fourth-quarter total revenues were $57.2 million, an 8% year-over-year increase, with Fanapt sales rising by 25% to $33.2 million [6] - Hetlioz's fourth-quarter net product sales fell by 18% to $16.4 million, while Ponvory's sales increased by 17% to $7.6 million [7] Operating Expenses - Operating expenses rose to $367.3 million in 2025 from $239.4 million in 2024, driven by increased SG&A expenses related to commercial launches and higher R&D costs [8] Cash Position - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $263.8 million, down $110.8 million from the previous year [9] Pipeline and Regulatory Updates - The FDA approved Nereus for motion-induced vomiting, marking a significant regulatory achievement for the company [11] - Vanda plans to initiate a phase III program for tradipitant in vomiting associated with GLP-1 agonists in the first half of 2026 [12] - The NDA for Bysanti is under FDA review with a PDUFA date of February 21, 2026 [13] - The company submitted the BLA for imsidolimab for generalized pustular psoriasis in Q4 2025 [14] Commercial Strategy - Vanda expanded its commercial infrastructure, increasing the Fanapt sales force from about 160 to 300 representatives by the end of 2025 [15] - For 2026, the company expects total revenues from currently marketed products to be between $230 million and $260 million, with a continued decline in Hetlioz sales anticipated [16] Future Guidance - The company does not provide cash guidance for 2026 but expects cash burn to exceed 2025 levels [17] - Vanda is also pursuing clinical development programs for Ponvory in psoriasis and ulcerative colitis, with ongoing studies for Bysanti and VQW-765 [19]

How AI is helping solve the labor issue in treating rare diseases https://t.co/DoNYBgzG8l ...

Regulators get nervous about custom treatments, especially for rare diseases with little or no prior clinical data behind them. The risks, in their eyes, are hard to quantify. That may be changing https://t.co/hHUSm2Gje2 ...

Financial Data and Key Metrics Changes - The company is focused on the upcoming data readout for setrusumab, which is expected by the end of December or January, marking a significant near-term value driver [2][34] - The company has achieved a 67% reduction in fracture rates from baseline in the phase 1/2 study, indicating strong efficacy [7][15] Business Line Data and Key Metrics Changes - The company is advancing its Osteogenesis Imperfecta (OI) program, which targets a patient population of at least 60,000 in the covered geographies, aiming to replicate the success of Crysvita [3][4] - The ORBIT trial has enrolled an additional 159 patients, maintaining a two-to-one randomization of setrusumab to placebo, with a focus on patients aged 5 to 26 [10][12] Market Data and Key Metrics Changes - The company is preparing for a market launch of setrusumab, which is positioned as a superior treatment compared to bisphosphonates, currently the only available treatment for OI [2][11] - The potential market for Sanfilippo is estimated at 3,000 to 5,000 patients, while GSD1A is slightly larger at 6,000 patients, indicating a strategic focus on rare disease markets [42] Company Strategy and Development Direction - The company is committed to not compromising the quality of data for the OI filing, despite the ambitious timeline for approval by the end of September [30][32] - The strategy includes leveraging AI for data analysis and document preparation to enhance efficiency in the filing process [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the probability of success for the final data readout, maintaining that the interim analyses have not negatively impacted their outlook [20][28] - The company is optimistic about achieving profitability within the timeframe of their recent monetization deal, which allows for revenue generation without immediate repayment obligations [93] Other Important Information - The company is actively working on gene therapy programs, with a focus on Sanfilippo and GSD1A, both of which are expected to have PDUFA dates within the PRV window [38][39] - The company has learned from previous regulatory feedback, applying those lessons to improve the quality of their gene therapy programs [40][42] Q&A Session Summary Question: What is the timeline for the data readout for setrusumab? - The company has defined the end of year as December or January for the data readout [34] Question: How does the company view the efficacy of bisphosphonates compared to setrusumab? - Management estimates the treatment effect of bisphosphonates to be around 20%, while setrusumab has shown a 67% reduction in fracture rates [14][15] Question: What is the company's approach to the upcoming regulatory filings? - The company plans to ensure high-quality data packages for regulatory submissions, emphasizing that they will not rush the process [30][32] Question: How does the company plan to address the market for Sanfilippo and GSD1A? - The company is confident in the clinical data for both programs and is preparing for timely submissions to the FDA [38][39]

All right, welcome back everybody. CNBC has learned that healthcare industry leaders have sent a letter to President Trump to the Health and Human Services Secretary Robert F. Kennedy Jr.. and the head of the FD FDA, Dr. . Marty McCary. The leaders who are speaking up here are lod lodging some frustration with the FDA when it comes to approvals of potentially life-saving therapeutics for rare diseases.The group of U letter signitories are made up of biotech leaders, patient advocates, and academics who work ...

Core Insights - Gan DX has achieved significant milestones in genomic testing, including identifying over 400 new disease gene relationships and reaching profitability under the leadership of Katherine Stuland [1][2][5] - The company is focusing on rare diseases, particularly among children and newborns, addressing a critical need as one in ten Americans has a rare disease, with half of them being children [4][11] Company Performance - Gan DX experienced a 56% increase in revenue last year, driven by strategic focus on areas with good reimbursement coverage such as epilepsy, autism, and developmental delays [5][9] - The company has successfully expanded its Medicaid coverage, with 35 states covering outpatient testing and 16 states covering NICU testing [14][15] Industry Context - The diagnostics industry faces unique challenges, including reimbursement issues where services are not always fully paid for, impacting access for patients [7][8] - There is a significant economic impact associated with rare diseases, estimated at a trillion dollars in the U.S., primarily due to the costs of treating symptoms without accurate diagnoses [24][25] Technological Advancements - Gan DX is leveraging AI to enhance its operations, improve diagnostic accuracy, and streamline the process of gathering patient information for better insurance coverage [16][21] - The company possesses the largest rare disease dataset in the U.S., enriched with both genotypic and phenotypic information, which aids in providing accurate diagnoses [19][20] Future Outlook - The goal is to enable early diagnosis and intervention for rare diseases, potentially screening every newborn at birth to connect them with individualized therapies [12][13] - The company is committed to reducing costs to improve access to genomic testing, ensuring that lack of insurance does not hinder patient care [15][13]

Core Insights - Soleno Therapeutics has appointed Mark W. Hahn as an independent director to its Board of Directors, enhancing the board's expertise with nearly 30 years of CFO-level experience in the biopharmaceutical sector [1][2] - The addition of Mr. Hahn brings the total number of board members to seven, which is expected to support the company's ongoing commercial launch of VYKAT™ XR [1][2] Company Overview - Soleno Therapeutics is focused on developing novel therapeutics for rare diseases, with its first commercial product, VYKAT™ XR, approved by the FDA on March 26, 2025 [11] - VYKAT™ XR is indicated for treating hyperphagia in patients aged 4 years and older with Prader-Willi syndrome (PWS) [6][11] Leadership and Experience - Mark W. Hahn has a strong background in financial leadership, having served as CFO for several companies, including Verona Pharma PLC and Dova Pharmaceuticals, where he played key roles in product launches and capital raising [2][3] - His experience includes overseeing Verona Pharma's phase 3 program and its acquisition by Merck & Co., Inc. for approximately $10 billion [2] Product Information - VYKAT™ XR is designed to address hyperphagia, a severe condition associated with PWS, which can significantly impact the quality of life for affected individuals [5][6] - The product is now commercially available to U.S. patients following its FDA approval [6][11]

Core Insights - Insmed Incorporated (NASDAQ: INSM) is recognized as one of the best performing healthcare stocks, focusing on rare diseases with significant unmet medical needs [1] - The recent FDA approval of Brinsupri for non-CF bronchiectasis has significantly boosted investor interest and stock performance, with shares rising nearly 9% [2] - Analysts have raised price targets for INSM, with estimates ranging from $135 to $240, reflecting the potential for Brinsupri to generate $7 billion in revenue by 2033 [2] Financial Performance - For Q2 2025, Insmed reported revenues of $107.4 million for ARIKAYCE, representing a 19% year-over-year increase, with a gross margin of 75.7% [3] - Despite the revenue growth, the company reported a net loss of $321.7 million [3] - Insmed completed a public offering, raising approximately $823 million to support pipeline development and commercialization efforts [3] Pipeline Developments - Insmed's pipeline includes several promising late-stage assets, with Brensocatib receiving FDA approval on August 12, 2025 [4] - The Treprostinil Palmitil Inhalation Powder (TPIP) program is advancing towards Phase 3 studies for pulmonary hypertension, expected to commence in late 2025 to early 2026 [4] - These developments position Insmed for continued growth and expansion in the rare disease market [4]